Gainers
Losers
Royal Caribbean is the standout at the open, up 7.56% to $301.81 and leading a 381-stock priority list. HSBC anchors the other end at -6.47%, a 14-point spread between the day's best and worst names.
Latest Activity
PodcastMad Money w/ Jim Cramer
Mad Money w/ Jim Cramer 10/26/26
- Cramer's bear case: a flood of IPOs and secondaries, $148B raised so far this year, drains the money that funds stocks
- Applied Materials down from $739 to $387: buy 25 shares now, add on the pattern, finish in the 200s
- Moderna after a parabolic move: let it come in before earnings, no buying parabolic charts
- Thermo Fisher CEO on a beat-and-raise, BlackBerry's turnaround, and CrowdStrike cyber worries on deck
The call that matters for holders here is supply: Cramer argues the equity and debt markets are nearly tapped out after Meta, Alphabet and SpaceX raisings, with Anthropic's S1 now in line. He stops short of calling a top while pushing for buybacks and takeovers over further deals, favoring staged buying in Applied Materials and patience on Moderna.
Gainers
Losers
American Tower opened up 8.07%, the only move above 4% on the upside across a 385-name board. Bloom Energy is off 11.67%, with Moderna, Infosys, GE Aerospace and AT&T sliding too.
- 1MRNAbearish1.7K comments · 12.4K upvotes
- 2NVDAsplit454 comments · 1.1K upvotes
- 3SPYbullish1.0K comments · 2.4K upvotes
- 4METAsplit830 comments · 1.5K upvotes
- 5GOOGLsplit459 comments · 769 upvotes
NVDAsouring fast
Moderna is pulling more chatter than the rest of the board combined, and the mood there is bearish even as its pipeline headlines pile up. Nvidia is souring fast, while traders stay split on Meta and Alphabet and keep leaning bullish on the broad index.
Source: RedditGainers
Losers
Moderna's 17.8% drop was the single biggest move at Tuesday's close, and four of the five worst performers were chip and photonics names. Spotify topped the winners.
Regular session
$205.66
-14.31%open $240.00
A 14.31% slide to $205.67 takes roughly $12 billion off an $84.9 billion biotech in a single session, one of the sharpest single-day drops this name has seen. Keep an eye on whether the $240 open gets reclaimed.
New 52-week high$242.08+2.4% vs prior high · 2026-10-15
Moderna just set a fresh 52-week high at $242.08, 2.36% above the peak it reached on October 15. A year ago the stock traded near $27.
Gainers
Losers
General Motors shed 7.5% into the close, the worst showing across 387 priority names and nearly double the next-biggest decline. GoPro and Clover Health anchored the other end, each up more than 7.5%.
Gainers
Losers
GoPro's 10.3% jump leads the open, with Moderna close behind and the entire downside capped under 3.5%. Across the priority names, the gains are doing all the work this morning.
54stocks hit new 52-week highs this week
- MRNAModerna$218.01+16.2%
- BOXBox$39.56+8.9%
- SUSuncor Energy$78.05+8.6%
- BPBP p.l.c.$50.21+6.9%
- SHELShell$106.66+6.5%
- DOCUDocuSign$74.65+6.0%
- PSXPhillips 66$293.17+5.6%
- PBRPetrobras$26+5.3%
- PBR-APetrobras$23.3+5.2%
- XOMExxon Mobil$178.98+5.1%
54 stocks printed fresh 52-week highs this week, and Big Oil showed up in force: Suncor, BP, Shell, Phillips 66, Petrobras and Exxon all cleared prior peaks. Moderna led the whole list, topping its old high by 16%.
MRNA Coverage
12:04pm ET
Investing
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands…
8:14am ET
Investing
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast. Three pharma giants report Thursday, and…
7:51am ET
Investing
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Broadcom, Conoco Phillips, HubSpot, MercadoLibre, Moderna, Occidental Petroleum, PNC Financial, Trimble, and More
Pre-Market Stock Futures: Futures are trading higher after a Monday bounce that saw all major indices finish higher; stocks closed well below their intraday highs, but it was a positive start after…
9:14am ET
Investing
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial. Moderna (NASDAQ:MRNA | MRNA…
11:31am ET
Investing
Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck’s Q3 Results on Oct. 29
Merck (NYSE:MRK | MRK Price Prediction) reports third-quarter results on Thursday, Oct. 29. KEYTRUDA still anchors the business, but I’ll be watching whether newer launches are growing fast enough to cushion the…
9:17am ET
Investing
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn’t stopped. Those numbers landed short of the…
1:55pm ET
Investing
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, even though its findings looked favorable on…
1:53pm ET
Investing
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%
Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.89 during the trading…
12:44pm ET
Investing
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide…
10:49am ET
Investing
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10%…
12:55pm ET
Investing
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA…
8:20am ET
Investing
Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers…
1:59pm ET
Investing
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
A protein-vaccine developer with no fresh catalyst just posted a double-digit gain that dwarfs what Moderna and Merck managed in the same session, and the explanation reveals something uncomfortable about how this…
11:48am ET
Investing
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine…
7:30am ET
Investing
3 Stocks That Have More Than Doubled the S&P 500’s Return This Year
Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a…
